Sign in

CIK 0001231457 · Non-accelerated filer<br>Smaller reporting company<br>Emerging growth company

GENELUX Corp

Sign in to watch
Ticker
GNLX
Exchange
Nasdaq
Industry
Pharmaceutical Preparations
FY end
Dec 31
Incorporated
DE
Entity type
operating
Phone
805-267-9889
Business address
2625 TOWNSGATE ROAD, SUITE 230, WESTLAKE VILLAGE, CA, 91361
Open-market buys, last 90 days
$0
in 0 filings
Open-market sales, last 90 days
$155,693
in 6 filings

Net −$155,693. Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.

Reading 71 more Form 4s from the SEC; this list fills in as they're read.

Date Insider Transaction Shares Price Value Owned after
2025-08-27 Cappello Joseph Chief Technical Officer Grant or award +107,500 159,766
2025-08-27 Cappello Joseph Chief Technical Officer Grant or award · Stock Option (Right to Buy) +142,500 142,500
2025-08-21 Zindrick Thomas President and CEO Sale −12,673 $3.33 $42K 542,940
2025-08-21 Yu Yong SVP, Clinical Development Sale −3,219 $3.36 $11K 146,817
2025-08-21 Cappello Joseph Chief Technical Officer Sale −1,270 $3.33 $4K 158,496
2025-08-21 Cappello Joseph Chief Technical Officer Sale −1,463 $3.36 $5K 157,033
2025-08-21 Smalling Ralph Head of Regulatory Sale −1,244 $3.36 $4K 69,746
2025-07-01 Groen Eric General Counsel & Secretary Grant or award · Stock Option (Right to Buy) +270,000 270,000
2025-06-06 Thomas John Director Gift −25,000 480,501
2025-05-12 Ryder Sean General Counsel Sale −4,475 $2.92 $13K 47,621
2025-05-12 Zindrick Thomas President and CEO Sale −10,764 $2.92 $31K 191,447
2025-05-12 Yu Yong VP, Clinical Trial Operations Sale −5,579 $2.92 $16K 47,640
2025-05-12 Cappello Joseph VP, Pharmaceutical Development Sale −4,737 $2.92 $14K 52,266
2025-05-12 Smalling Ralph Head of Regulatory Sale −1,259 $2.92 $4K 34,760
2025-03-14 Smalling Ralph Head of Regulatory Grant or award +4,172 36,019
2025-03-14 Cappello Joseph VP, Pharmaceutical Development Grant or award +13,350 57,003
2025-03-14 Yu Yong VP, Clinical Trial Operations Grant or award +13,350 53,219
2025-03-14 Ryder Sean General Counsel Grant or award +10,708 52,096
2025-03-14 Zindrick Thomas President and CEO Grant or award +30,339 202,211
2025-01-31 Pulisic Matthew Chief Financial Officer Grant or award · Stock Option (right to buy) +275,000 275,000

Page 5 of 9 · 170 trades